about
A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive declineBig data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledgeRegulation of peripheral metabolism by substrate partitioning in the brain.Effects of estradiol on the thermoneutral zone and core temperature in ovariectomized rats.Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-makingOvercoming obstacles to repurposing for neurodegenerative disease.Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.Ambient temperature and 17β-estradiol modify Fos immunoreactivity in the median preoptic nucleus, a putative regulator of skin vasomotion.Role of Hypothalamic Creb-Binding Protein in Obesity and Molecular Reprogramming of Metabolic SubstratesModulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes.Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.Progress in novel cognitive enhancers for cognitive aging and Alzheimer's disease.Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions.Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery.Estrogens iron out the details: a novel direct pathway for estrogen control of iron homeostasisRecognizing the Spectrum of Cognitive Impairment to Advance Drug DiscoveryEpilepsy Benchmarks Area II: Prevent Epilepsy and Its ProgressionEpilepsy Benchmarks Area I: Understanding the Causes of the Epilepsies and Epilepsy-Related Neurologic, Psychiatric, and Somatic ConditionsEpilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side EffectsEpilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span
P50
Q26740260-30D576B9-A1CF-4738-B8D6-AF6A3C06AA7AQ26745466-02ED4E81-7CE9-4963-A7E7-DF0E60FB54F4Q27692584-66240BEF-0461-40C7-97CF-7AEB4FF14088Q30433033-E2276297-8473-4B82-BD81-F6E1F6B620F2Q30978649-B8E947FC-D88A-4DC6-A2B6-9352C0E55E14Q34287015-CAF8326C-2913-402E-9C91-46D1591B8D61Q34330929-90AA3AAC-67C4-434F-A16E-A295B690E7FDQ35046872-A5035426-88C0-403C-9C03-9DC48A09F0FAQ36188924-7A63AE23-9A3C-4D84-A4A7-EA37E4154ADCQ37324733-027DF8B8-D2F4-4B49-AA5D-476C0B6C2EDEQ38199970-6DE8DBC3-3453-477E-8C68-DDA4EAB7C5FBQ38651750-C00898AA-3047-438E-AD56-9B79EF5FA0C4Q45010732-A1D11C37-2F7E-4109-979E-CF5608ACB42CQ46618457-259E4F8D-BABF-4041-AD2A-7DDB53423FC7Q84450819-5B1A19F3-55B2-4EBC-BB02-C46AF89B25BBQ87446635-738B665C-4A71-4080-9C35-5068F97F5813Q92638804-A503B586-26AE-4174-9387-19299704CB54Q92833487-819E3489-0770-4617-A74A-D98A00E84662Q92833495-74110B77-D556-4FE4-BB17-BFAF3A423D5AQ92885250-FE3B43C9-BB56-47F4-897C-0C15BD61833D
P50
description
researcher ORCID ID = 0000-0003-1149-4192
@en
wetenschapper
@nl
name
Penny A Dacks
@ast
Penny A Dacks
@en
Penny A Dacks
@es
Penny A Dacks
@nl
type
label
Penny A Dacks
@ast
Penny A Dacks
@en
Penny A Dacks
@es
Penny A Dacks
@nl
prefLabel
Penny A Dacks
@ast
Penny A Dacks
@en
Penny A Dacks
@es
Penny A Dacks
@nl
P106
P1153
35558442300
P31
P496
0000-0003-1149-4192